Aspire Biopharma (ASBP) announced the brand name BUZZ BOMB and anticipated market launch for its novel sublingual pre-workout supplement. BUZZ BOMB features 50mg of caffeine and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts maximize their performance potential. Aspire has commenced initial production of BUZZ BOMB, its single serving pre-workout caffeine supplement utilizing Aspire’s patent-pending and proprietary sublingual delivery technology.The pre-workout formula is conveniently packaged in a single serving packet for easy on-the-go use. Consumers will have a choice of six BUZZ BOMB flavors, including Tropical Fruit, Mixed Berry, Watermelon, Lemon Lime, Peach Mango, and Mocha Coffee. The Company expects to begin expanded pre-launch consumer testing of this supplement product during the second quarter of 2025. In August, the Company will have a booth and be an event sponsor at two of the largest fitness conferences in the nation where over 50,000 people interested in health, fitness, optimization, nutrition, and overall wellbeing will be able to taste, sample, and experience the BUZZ BOMB pre-workout supplement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASBP:
- Aspire announces first patient dosed in Phase 1 trial of aspirin formulation
- Aspire Biopharma files to sell 8.33M shares of common stock for holders
- Aspire announces IRB approval for in-human trial of aspirin formulation
- Aspire commences initial production of pre-workout performance supplement
- Aspire announces Phase 1 trial initiation of high-dose aspirin formulation